Regenxbio DRC A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy with RGX-314 in Subjects with Neovascular AMD (nAMD)

Administered By

Awarded By

Contributors

Start/End

  • June 21, 2018 - March 31, 2021